bioRxiv · 10.1101/2022.06.15.496249
Multi-omics alleviates the limitations of panel-sequencing for cancer drug response prediction
Abstract
Comprehensive genomic profiling using cancer gene panels has been shown to improve treatment options for a variety of cancer types. However, genomic aberrations detected via such gene panels dont necessarily serve as strong predictors of drug sensitivity. In this study, using pharmacogenomics datasets of cell lines, patient-derived xenografts, and ex-vivo treated fresh tumor specimens, we demonstrate that utilizing the transcriptome on top of gene panel features substantially improves drug response prediction performance in cancer.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Baranovskii, A., Gunduz, I. B., Franke, V., Uyar, B., Akalin, A.. 2022-06-17. Multi-omics alleviates the limitations of panel-sequencing for cancer drug response prediction. https://doi.org/10.1101/2022.06.15.496249
Cite the original work for its findings. Save a collection to share your selection of sources.